Press release New study: Circulating epithelial tumor cells as prognostic markers in prostate cancer

Wed, 05 Mar 2025 10:02:46 +0100

Bayreuth, February 25th, 2025 A recent study conducted by the laboratory Pachmann in Bayreuth, Germany, and the Department of Radiation Oncology at the University Hospital of Jena, Germany, has shown that circulating epithelial tumor cells (CETC/CTC) can be used as a biomarker to assess the risk of recurrence in prostate cancer...


Member of the German Bundestag Johannes Wagner visits Laboratory Pachmann: Appeal to the government to strengthen small and medium-sized enterprises in the medical sector

Mon, 24 Feb 2025 14:59:45 +0100

Member of the German Bundestag (National parliament of the Federal Republic of Germany) Johannes Wagner visited the internationally active laboratory Pachmann in Bayreuth to gain an insight into the challenges facing small and medium-sized enterprises (SMEs) in the medical sector. The visit focused on the urgent need for government support in...


Effectively supporting and accompanying cancer therapies

Mon, 17 Feb 2025 12:39:04 +0100

Liquid Biopsy offers new perspectives in cancer treatment. With blood tests, cancer can be monitored, therapies can be checked for their effectiveness and changes in tumor behavior can be detected at an early stage. This allows the therapy to be individually adapted to ensure the most effective treatment possible - an...


Laboratory Dr. Pachmann/maintrac® involved in study in Scientific Report

Mon, 03 Feb 2025 12:45:09 +0100

The laboratory Dr. Pachmann in Bayreuth, in collaboration with the University and University Hospital of Regensburg, played a key role in conducting the study “Patientderived xenografts from circulating cancer stem cells as a preclinical model for personalized pancreatic cancer research” [Wagner et al., 2025], which was published in the journal Scientific...



Alle erlauben Nur notwendige Durch die weitere Nutzung der Seite stimmen Sie der Verwendung von Cookies zu. Weitere Informationen